FrancophonIA/ELRC3.0 huggingface dataset:
English: The most common side effects with Plenadren (seen in more than 1 patient in 10) are fatigue (tiredness), diarrhoea, vertigo (feeling dizzy) and headache.
Estonian: Plenadreni kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on väsimus, kõhulahtisus, pööritustunne ja peavalu.
English: This may be given as Plenadren tablets twice or three times daily or as conventional immediate-release tablets or injections, either alone or in combination with Plenadren.
Estonian: Seda võib anda Plenadreni tablettidena 23 korda ööpäevas või tavaliste toimeainet kiiresti vabastavate tablettidena või süstidena, kas iseseisva ravina või koos Plenadreniga.
English: Adrenal insufficiency (including primary insufficiency or Addison's disease) is a condition where the adrenal glands (located just above the kidneys) do not produce enough of a steroid hormone called cortisol (also known as the stress hormone because it is released in response to stress).
Estonian: Neerupealiste puudulikkus (sealhulgas neerupealiste primaarne puudulikkus ehk Addisoni tõbi) on seisund, kus neerupealistes (näärmed neerude ülaosas) tekib liiga vähe steroidhormooni kortisooli, mis tavaliselt tekib reaktsioonina stressile.
English: Plenadren is a medicine used to treat adrenal insufficiency in adults.
Estonian: Plenadren on ravim, mida kasutatakse neerupealiste puudulikkuse raviks täiskasvanutel.
English: Hydrocortisone replaces the natural cortisol that is missing in patients with adrenal insufficiency.
Estonian: Hüdrokortisoon asendab looduslikku kortisooli, mis neerupealiste puudulikkusega patsientidel organismis puudub.
English: Because the number of patients with adrenal insufficiency is low, the disease is considered ‘rare', and Plenadren was designated an ‘orphan medicine' (a medicine used in rare diseases) on 22 May 2006.
Estonian: Et neerupealise puudulikkusega patsientide arv on väike ja see haigus esineb harva, nimetati Plenadren 22. mail 2006 harvikravimiks.
English: For practical information about using Plenadren, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Plenadreni kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: The overall amount of cortisol absorbed into the blood was around 20% lower in patients taking Plenadren compared with patients taking conventional hydrocortisone treatment.
Estonian: Verre imendunud kortisooli üldkogus oli Plenadreni võtvatel patsientidel ligikaudu 20% võrra väiksem kui tavalist hüdrokortisoonravi saavatel patsientidel.
English: How does Plenadren work?
Estonian: Kuidas Plenadren toimib?
English: For the full list of all side effects and restrictions with Plenadren, see the package leaflet.
Estonian: Plenadreni kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: For more information about treatment with Plenadren, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Plenadreniga toimuva ravi kohta lisateavet, lugege pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: What benefits of Plenadren have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Plenadreni kasulikkus?
English: The active substance in Plenadren, hydrocortisone, is the pharmaceutical form of cortisol, the main steroid hormone secreted by the adrenal gland.
Estonian: Plenadreni toimeaine hüdrokortisoon on neerupealise eritatava peamise steroidhormooni kortisooli farmatseutiline vorm.
English: Plenadren, given once per day, was compared with conventional hydrocortisone treatment, which is given three times per day.
Estonian: Uuringus võrreldi üks kord ööpäevas võetavat Plenadreni tavalise hüdrokortisoonraviga, mis toimus kolm korda ööpäevas.
English: How is Plenadren used?
Estonian: Kuidas Plenadreni kasutatakse?
English: Because it is available as a modified-release tablet, Plenadren releases hydrocortisone over a longer period of time allowing for a once-daily dosing.
Estonian: Et Plenadreni ravivorm on toimeainet modifitseeritult vabastav tablett, vabaneb hüdrokortisoon Plenadrenist pika aja jooksul, mistõttu saab ravimit võtta üks kord ööpäevas.
English: It is taken early in the morning to mimic the fact that in healthy people the blood level of cortisol increases early in the morning.
Estonian: Ravimi võtmisega varahommikul imiteeritakse terve organismi toimimist: tavaliselt suureneb kortisooli sisaldus veres varahommikul.
English: Plenadren can only be obtained with a prescription.
Estonian: Plenadren on retseptiravim.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that Plenadren achieved satisfactory levels of cortisol during the treatment of patients with adrenal insufficiency.
Estonian: Inimravimite komitee märkis, et Plenadreniga ravitud neerupealiste puudulikkusega patsientidel saavutati kortisooli rahuldav sisaldus veres.
English: In patients taking Plenadren the cortisol levels achieved were considered to be satisfactory for patients with adrenal insufficiency.
Estonian: Plenadreni võtnud patsientide kortisooli sisaldust veres peeti neerupealiste puudulikkusega patsientidel rahuldavaks.
English: Ristfor is taken twice a day.
Estonian: Ristfori võetakse kaks korda ööpäevas.
English: What measures are being taken to ensure the safe and effective use of Ristfor?
Estonian: Mis meetmed võetakse, et tagada Ristfori ohutu ja efektiivne kasutamine?
English: The full EPAR for Ristfor can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Ristfori kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Ristfor is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Ristfori võimalikult ohutu kasutamine.
English: This authorisation was based on the authorisation granted to Janumet in 2008 (‘informed consent').
Estonian: Müügiluba põhineb 2008. aastal antud Janumeti müügiloal (teabel põhinev nõusolek).
English: Why has Ristfor been approved?
Estonian: Miks Ristfor heaks kiideti?
English: The European Commission granted a marketing authorisation valid throughout the EU for Ristfor on 15 March 2010.
Estonian: Euroopa Komisjon andis Ristfori müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 15. märtsil 2010.
English: The results of three further studies were used to support the use of Ristfor.
Estonian: Ristfori kasutamise toetamiseks kasutati kolme muu uuringu tulemusi.
English: What is the risk associated with Ristfor?
Estonian: Mis riskid Ristforiga kaasnevad?
English: Sitagliptin has been authorised in the European Union (EU) as Januvia and Xelevia since 2007 and as Tesavel since 2008.
Estonian: Sitagliptiinil on Euroopa Liidus müügiluba ravimitena Januvia ja Xelevia alates 2007. aastast ning ravimina Tesavel 2008. aastast.
English: Ristfor sitagliptin / metformin hydrochloride
Estonian: Ristfor sitagliptiin/metformiinvesinikkloriid
English: The company presented the results of three studies of Januvia/Xelevia to support the use of Ristfor in patients who were not satisfactorily controlled on their existing metformin treatment.
Estonian: Ettevõte esitas Januvia/Xelevia kolme uuringu tulemused, et toetada Ristfori kasutamist patsientidel, kelle senine metformiiniravi ei andnud rahuldavaid tulemusi.
English: The CHMP decided that Ristfor's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Ristfori kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The strength of tablet to use depends on the dose of the other diabetes medicines that the patient was taking before.
Estonian: Kasutatava tableti tugevus sõltub patsiendi varem võetud diabeediravimite annusest.
English: The company carried out additional studies to show that the active substances in Ristfor are absorbed by the body in the same way as the two medicines given separately.
Estonian: Ettevõte tegi ka lisauuringud, et määrata kindlaks, kas Ristfori toimeained imenduvad organismis samal viisil kui kumbki aine eraldi manustatuna.
English: It is available as tablets (50 mg sitagliptin and 850 mg metformin hydrochloride; 50 mg sitagliptin and 1,000 mg metformin hydrochloride).
Estonian: Ravimit turustatakse tablettidena (50 mg sitagliptiini ja 850 mg metformiinvesinikkloriidi ning 50 mg sitagliptiini ja 1000 mg metformiinvesinikkloriidi).
English: Ristfor must not be used in patients who have diabetic ketoacidosis or pre coma (dangerous conditions that can occur in diabetes), problems with the kidneys or liver, conditions that may affect the kidneys, or a disease that causes a reduced supply of oxygen to the tissues such as failure of the heart or lungs or a recent heart attack.
Estonian: Ravimit ei tohi kasutada patsiendid, kellel on diabeetiline ketoatsidoos või kooma eelseisund (diabeedi korral esineda võivad ohtlikud seisundid), neeru- või maksaprobleemid, neerukahjustuse riskiga seisundid või haigus, mis vähendab kudede hapnikuvarustust, näiteks südame- või kopsupuudulikkus või hiljutine südameinfarkt.
English: For more information about treatment with Ristfor, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Ristforiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Serious side effects reported with Ristfor include pancreatitis (inflammation of the pancreas) and hypersensitivity (allergic reactions).
Estonian: Ristfori kohta teatatud rasked kõrvalnähud on pankreatiit (kõhunäärmepõletik) ja ülitundlikkus (allergilised reaktsioonid).
English: Ristfor was more effective than metformin alone.
Estonian: Ristfor oli efektiivsem kui ainuravimina kasutatud metformiin.
English: This document is a summary of the European Public Assessment Report (EPAR) for Ristfor.
Estonian: See on ravimi Ristfor Euroopa avaliku hindamisaruande kokkuvõte.
English: Ristfor is a diabetes medicine that contains two active substances, sitagliptin and metformin hydrochloride.
Estonian: Ristfor on diabeediravim, mis sisaldab kaht toimeainet, sitagliptiini ja metformiinvesinikkloriidi.
English: What is Ristfor?
Estonian: Mis on Ristfor?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ristfor.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ristfor, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Ristfori omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: In the first of the three further studies, Ristfor was more effective than metformin or sitagliptin alone.
Estonian: Kolmest lisauuringust esimeses oli Ristfor efektiivsem kui ainult metformiin või sitagliptiin.
English: As a result of the action of both active substances, blood glucose levels are reduced and this helps to control type 2 diabetes.
Estonian: Mõlema toimeaine toimel vere glükoosisisaldus väheneb ning see aitab II tüüpi diabeeti reguleerida.
English: Other information about Ristfor:
Estonian: Muu teave Ristfori kohta
English: If Ristfor is taken with a sulphonylurea or insulin, the dose of the sulphonylurea or insulin may need to be lowered, to avoid hypoglycaemia (low blood sugar levels).
Estonian: Kui Ristfori võetakse koos sulfonüüluurearavimiga või insuliiniga, võib olla vaja vähendada sulfonüüluurearavimi või insuliini annust, et ennetada hüpoglükeemiat (vere normaalsest väiksem glükoosisisaldus).
English: • in patients who are not satisfactorily controlled on metformin (a diabetes medicine) used on its own;
Estonian: • patsientidel, kelle haigus ei allu piisavalt ravile üksnes metformiiniga (diabeediravim);
English: The active substances in Ristfor, sitagliptin and metformin hydrochloride, each have a different mode of action.
Estonian: Ristfori toimeained sitagliptiin ja metformiinvesinikkloriid on kumbki eri toimega.
English: The first included 1,091 patients who were not satisfactorily controlled on diet and exercise alone and compared the effect of Ristfor with that of metformin or sitagliptin alone.
Estonian: Esimeses uuringus osales 1091 patsienti, kelle seisund ei olnud ainult dieedi ja füüsilise koormuse kasutamisel rahuldav, ja selles võrreldi Ristfori toimet ainult metformiini või sitagliptiini toimega.
English: Metformin works mainly by inhibiting glucose production and reducing its absorption in the gut.
Estonian: Metmorfiin põhiliselt inhibeerib glükoosi tekkimist ja vähendab selle imendumist sooles.
English: Sitagliptin is a dipeptidyl-peptidase-4 (DPP 4) inhibitor.
Estonian: Sitagliptiin on ensüümi dipeptidüülpeptidaas-4 (DPP-4) inhibiitor, mille toime seisneb inkretiinhormoonide lagunemise blokeerimises.
English: The second included 278 patients who were not satisfactorily controlled on the combination of metformin and rosiglitazone (a PPAR-gamma agonist) and compared the effects of adding sitagliptin or placebo.
Estonian: Teises uuringus osales 278 patsienti, kelle haigusseisundit ei saanud rahuldavalt ravida metformiini ja rosiglitasooni (PPARγ agonist) kombinatsiooniga; uuringus võrreldi sitagliptiini või platseebo lisamise mõju.
English: Ristfor is used in patients with type 2 diabetes to improve the control of blood glucose (sugar) levels.
Estonian: Ristfori kasutatakse II tüüpi diabeediga patsientide raviks, et parandada vere glükoosisisalduse reguleeritavust organismis.
English: What benefit has Ristfor shown during the studies?
Estonian: Milles seisneb uuringute põhjal Ristfori kasulikkus?
English: Hypoglycaemia has been reported in combination with a sulphonylurea in 13.8% of patients and with insulin in 10.9% of patients.
Estonian: Patsiente, kellel teatati hüpoglükeemia esinemisest, oli Ristfori koos sulfonüüluurearavimiga kasutanute seas 13,8% ja Ristfori koos insuliiniga kasutanute seas 10,9%.
English: What is Ristfor used for?
Estonian: Milleks Ristfori kasutatakse?
English: How is Ristfor used?
Estonian: Kuidas Ristfori kasutatakse?
English: How has Ristfor been studied?
Estonian: Kuidas Ristfori uuriti?
English: The third study compared sitagliptin with placebo, when used as an add-on to glimepiride (another sulphonylurea), with or without metformin, in 441 patients.
Estonian: Kolmandas uuringus (441 patsienti) võrreldi sitagliptiini platseeboga, kui ravimit kasutati lisaks glimepiriidile (samuti sulfonüüluurearavim), koos metformiiniga või ilma.
English: For the full list of all side effects reported with Ristfor, see the package leaflet.
Estonian: Ristfori kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The medicine can only be obtained with a prescription.
Estonian: Ristfor on retseptiravim.
English: How does Ristfor work?
Estonian: Kuidas Ristfor toimib?
English: In the second, HbA1c levels were reduced by 1.03% after 18 weeks in patients adding sitagliptin to metformin and rosiglitazone, compared with a fall of 0.31% in those adding placebo.
Estonian: Teises uuringus vähenes sitagliptiini lisamisel metformiinile ja rosiglitasoonile 18 nädala järel HbA1c sisaldus veres 1,03% võrra, kuid platseebo lisamisel vähenes see 0,31% võrra.
English: Adding 100 mg sitagliptin to metformin reduced HbA1c levels by 0.67% (from around 8.0%) after 24 weeks, compared with a fall of 0.02% in the patients adding placebo.
Estonian: 100 mg sitagliptiini lisamine metformiinile vähendas 24 nädala järel HbA1c sisaldust veres 0,67% võrra (enne ravi oli sisaldus ligikaudu 8,0%),
English: Ristfor should be taken with food to avoid any stomach problems caused by metformin.
Estonian: Sitagliptiini suurim ööpäevane annus on 100 mg. Ristfori peab võtma koos söögiga, et ennetada metformiini tõttu tekkivaid maokahjustusi.
English: Finally, they were reduced by 0.59% after 24 weeks in patients adding sitagliptin to insulin, compared with a fall of 0.03% in those adding placebo.
Estonian: Sitagliptiini lisamisel insuliinile vähenes 24 nädala järel HbA1c sisaldus veres 0,59% võrra, kuid platseebo lisamisel vähenes see 0,03% võrra.
English: (other types of diabetes medicine) in patients who are not satisfactorily controlled on this medicine and metformin.
Estonian: • koos sulfonüüluurearavimiga, PPARγ agonistiga, nt tiasolidiindioonravimiga, või insuliiniga (samuti diabeediravimid) patsientidel, kelle vere glükoosisisaldust ei saa ainult selle ravimi ja metformiiniga rahuldavalt reguleerida.
English: EMA/622300/2010 EMEA/V/C/002230
Estonian: EMA/CVMP/622300/2010 EMEA/V/C/002230
English: The second injection is given three to four weeks later.
Estonian: Teine süst tehakse kolm kuni neli nädalat hiljem.
English: Two studies were conducted in sheep and cattle to establish the period of protection provided by the vaccine.
Estonian: Lammastel ja veistel korraldati kaks uuringut, et teha kindlaks vaktsiini tekitatav kaitseperiood.
English: The duration of protection of the vaccine in both sheep and cattle was found to be 12 months.
Estonian: Vaktsiini kaitseperiood nii lammastel kui ka veistel oli 12 kuud.
English: The European Commission granted a marketing authorisation valid throughout the European Union, for BTVPUR AlSap 1 on 17 December 2010.
Estonian: Euroopa Komisjon andis vaktsiini BTVPUR AlSap 1 müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 17. detsembril 2010.
English: The first injection is given from one month of age in animals that have never been exposed to the disease, and from two-and-a-half months if the animal's mother is already immune to the disease.
Estonian: Esimene süst tehakse vähemalt ühe kuu vanustele noorloomadele, kes ei ole haigusega varem kokku puutunud, ja vähemalt kahe ja poole kuu vanustele noorloomadele, kes on sündinud juba immuunsel emasloomal.
English: Vaccination may be followed by a small local swelling at the injection site, which normally resolves within five weeks.
Estonian: Pärast vaktsineerimist võib loomal tekkida kerge turse süstekohas, mis tavaliselt taandub viie nädala jooksul.
English: There can be a slight rise in body temperature, usually no more than 1 °C, in the 24 hours following vaccination.
Estonian: Looma kehatemperatuur võib vaktsineerimisele järgneva 24 tunni jooksul natuke tõusta, tavaliselt kuni 1 ℃ võrra.
English: In the future, if the animals are exposed to the bluetongue virus, their immune system will be able to produce antibodies more quickly.
Estonian: Kui loomad puutuvad hiljem kokku lammaste katarraalse palaviku viirusega uuesti, tekivad antikehad kiiremini.
English: The safety of the vaccine was studied in two main overdose laboratory safety studies carried out in sheep and cattle.
Estonian: Vaktsiini ohutust uuriti kahes laboratoorses ohutuse põhiuuringus, milles manustati lammastele ja veistele üleannus.
English: In 2013 the CVMP considered that the submitted data were adequate for the authorisation of BTVPUR AlSap 1 to convert to a normal status.
Estonian: 2013. aastal otsustas veterinaarravimite komitee, et esitatud andmed on piisavad, et muuta BTVPUR AlSap 1 müügiluba tavakorras väljastatuks.
English: The studies showed that the vaccine is safe for sheep and cattle and that it reduces the signs of the disease and prevents viraemia in animals from one month of age that are infected with bluetongue virus serotype 1.
Estonian: Uuringud näitasid, et vaktsiin on lammastele ja veistele ohutu ning leevendab haiguse sümptomeid ja ennetab vireemiat lammaste katarraalse palaviku viiruse serotüübiga 1 nakatunud vähemalt ühe kuu vanustel loomadel.
English: The studies also showed that the vaccine can be used in pregnant sheep and cattle as well as lactating cattle.
Estonian: Samuti näitasid uuringud, et vaktsiini tohib kasutada lammastel ja veistel tiinuse ning veistel laktatsiooni ajal.
English: The effectiveness of the vaccine was studied in three main laboratory trials using a vaccine with bluetongue serotype 1 in sheep and cattle of young age.
Estonian: Vaktsiini efektiivsust uuriti kolmes laboratoorses põhikatses, mille käigus manustati lammaste katarraalse palaviku serotüüpi 1 sisaldavat vaktsiini noorlammastele ja mullikatele.
English: It contains inactivated (killed) bluetongue serotype 1 virus.
Estonian: See sisaldab lammaste katarraalse palaviku inaktiveeritud (hävitatud) viiruse serotüüpi 1.
English: This means that it was not possible to obtain complete information about BTVPUR AlSap 1 at the time of the initial authorisation.
Estonian: See tähendab, et vaktsiini BTVPUR AlSap 1 kohta ei olnud esmase müügiloa andmisel võimalik saada täielikku teavet.
English: When it is given to sheep and cattle, the animals' immune systems recognise the viruses as ‘foreign' and make antibodies against them.
Estonian: Kui seda süstitakse lammastele ja veistele, peab immuunsüsteem vaktsiinis sisalduvaid viiruseid võõraks ja tekitab nende vastu antikehi.
English: BTVPUR AlSap 1 contains a bluetongue virus that has been inactivated so that it cannot cause the disease.
Estonian: BTVPUR AlSap 1 sisaldab lammaste katarraalse palaviku viirust, mis on inaktiveeritud ega suuda seetõttu haigust tekitada.
English: BTVPUR AlSap 1 contains bluetongue virus of one types (‘serotype 1').
Estonian: BTVPUR AlSap 1 sisaldab lammaste katarraalse palaviku viiruse üht tüüpi (serotüüp 1).
English: The CVMP concluded that the benefits of BTVPUR AlSap 1 exceed the risks for active immunisation of sheep and cattle to prevent infection, viraemia and clinical signs caused by the bluetongue virus serotype 1, and recommended that BTVPUR AlSap 1 be given a marketing authorisation.
Estonian: Veterinaarravimite komitee järeldas, et vaktsiini BTVPUR AlSap 1 kasulikkus lammaste ja veiste aktiivsel immuniseerimisel, mille eesmärk on ennetada lammaste katarraalse palaviku viiruse serotüübi 1 põhjustatud infektsiooni, vireemiat ja kliiniliste sümptomite avaldumist, on suurem kui sellega kaasnevad riskid, ning soovitas anda vaktsiini BTVPUR AlSap 1 müügiloa.
English: The benefitrisk balance may be found in the scientific discussion module of this EPAR.
Estonian: Ravimi kasulikkuse ja riski suhe on käesoleva Euroopa avaliku hindamisaruande teadusliku arutelu kokkuvõttes.
English: The company also presented results from a series of trials conducted with vaccines of similar composition but including different serotypes from the one in BTVPUR AlSap 1 in order to extrapolate further conclusions on the effectiveness of the vaccine.
Estonian: Samuti esitas ettevõte vaktsiini efektiivsuse järelduste edasiseks ekstrapoleerimiseks tulemusi mitmest katsest, milles kasutati vaktsiiniga BTVPUR AlSap 1 sarnase koostisega, kuid muid serotüüpe sisaldavaid vaktsiine.
English: BTVPUR AlSap 1 is a vaccine.
Estonian: BTVPUR AlSap 1 on vaktsiin.
English: The withdrawal period for BTVPUR AlSap 1 for meat and milk for cattle and sheep is zero days.
Estonian: Veiste ja lammaste liha ja piima keeluperiood vaktsiini BTVPUR AlSap 1 manustamisel on 0 päeva.
English: BTVPUR AlSap 1 is used in sheep and cattle to protect them against bluetongue disease, an infection caused by the bluetongue virus which is transmitted by midges..
Estonian: BTVPUR AlSap 1 kasutatakse lammaste ja veiste kaitsmiseks lammaste katarraalse palaviku eest (nakkushaigus, mida põhjustab lammaste katarraalse palaviku viirus ja mida levitavad teatud habesääsklased).
English: What is BTVPUR AlSap 1?
Estonian: Mis on BTVPUR AlSap 1?